Faculty profile

Sheng-Xiang Lin

ResearcherMolecular MedicineUniversité Laval

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a Université Laval directory, so their courses may be missing. Find their university profile.

Sheng-Xiang Lin

Researcher

Molecular Medicine

Health Sciences

Université Laval

Quebec City, Quebec, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
8 publications in the last five years, latest in 2026.
Senior (last) author on 6 recent papers, a sign of leading a research group.
Principal investigator on 7 research grants (6 CIHR, 1 NSERC), most recently in 2023.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Antivirals Combination Coronavirus Ferret Hamster Modeling Polymerase Repurposing

Latest papers

Developing Potential Endocrine Therapy Controlling Estradiol and DHT by Targeting 17β-HSD7 Against ER+ Breast Cancer.
Cells · 2026 · senior author
Search and prove of efficient inhibitors against papain-like protease from SARS-CoV-2.
Journal of virological methods · 2026 · senior author
A review on hemostatic materials: Past, present and future developments.
Biomaterials advances · 2026

All 56 publications

Latest funding

Pre-clinical pharmacokinetic and efficacy assays with an efficient 17beta-hydroxysteroid dehydrogenase type 7 inhibitor for breast cancer therapy
CIHR · 2023 · Nominated PI
$100,000
COVID-19 Variant Supplement - Innovative therapeutic approaches for the 2019-novel coronavirus
CIHR · 2021 · Principal investigator
$50,000
COVID-19 Variant Network - Innovative therapeutic approaches for the 2019-novel coronavirus
CIHR · 2021 · Principal investigator
$100,000

All 15 grants and awards

56 publications.

Developing Potential Endocrine Therapy Controlling Estradiol and DHT by Targeting 17β-HSD7 Against ER+ Breast Cancer.

Wang R, Wang X, Su P, Roy J, Poirier D, Lin SX

Cells2026Senior author

DOI: 10.3390/cells15151345 PMID: 42587755

Search and prove of efficient inhibitors against papain-like protease from SARS-CoV-2.

Zhang W, Chen XY, Lin SX

Journal of virological methods2026Senior author

DOI: 10.1016/j.jviromet.2025.115329 PMID: 41423169

A review on hemostatic materials: Past, present and future developments.

Chen XY, Xiao A, Wang Y, Lin SX, Rodrigue D

Biomaterials advances2026

DOI: 10.1016/j.bioadv.2026.214830 PMID: 41926810

Synthesis and characterization of targeted 17β-hydroxysteroid dehydrogenase type 7 inhibitors.

Sancéau JY, Maltais R, Zhou M, Lin SX, Poirier D

The Journal of steroid biochemistry and molecular biology2024

DOI: 10.1016/j.jsbmb.2024.106544 PMID: 38754521

New insights into the substrate inhibition of human 17β-hydroxysteroid dehydrogenase type 1.

Li T, Song X, Stephen P, Yin H, Lin SX

The Journal of steroid biochemistry and molecular biology2023Senior author

DOI: 10.1016/j.jsbmb.2023.106246 PMID: 36634828

Deep Drug Discovery of Mac Domain of SARS-CoV-2 (WT) Spike Inhibitors: Using Experimental ACE2 Inhibition TR-FRET Assay, Screening, Molecular Dynamic Simulations and Free Energy Calculations.

Iqbal S, Lin SX

Bioengineering (Basel, Switzerland)2023Senior author

DOI: 10.3390/bioengineering10080961 PMID: 37627846

Search of Novel Small Molecule Inhibitors for the Main Protease of SARS-CoV-2.

Zhang W, Lin SX

Viruses2023Senior author

DOI: 10.3390/v15020580 PMID: 36851795

CRIF1-CDK2 Interface Inhibitors Enhance Taxol Inhibition of the Lethal Triple-Negative Breast Cancer.

Sang X, Belmessabih N, Wang R, Stephen P, Lin SX

Cancers2022Senior author

DOI: 10.3390/cancers14040989 PMID: 35205737

An unprecedented endocrine target for ovarian cancer: inhibiting 17β-HSD7 supresses cancer cell proliferation and arrests G2/M cycle.

Wang R, Li T, Li G, Lin SX

American journal of cancer research2021Senior author

PMID: 34873465

The multi-specific human 17 beta-hydroxysteroid dehydrogenase type 7: Non-competitive inhibitors can target different catalyses to facilitate breast cancer treatment.

Thériault JF, Poirier D, Lin SX

The Journal of steroid biochemistry and molecular biology2021Senior author

DOI: 10.1016/j.jsbmb.2021.105963 PMID: 34400276

Pre-clinical pharmacokinetic and efficacy assays with an efficient 17beta-hydroxysteroid dehydrogenase type 7 inhibitor for breast cancer therapy

Nominated PICIHR2023Project Grant - PA: Breast Cancer Research

Principal investigators: Lin, Sheng-Xiang

Keywords: Drug Absorption, Distribution, Metabolism And Excretion; Drug Efficacy And Toxicity; Hormone-Dependent Breast Cancer; Joint Targeting Of Sex-Hormone Syntheses; Pre-Clinical Assay Of An Efficient 17beta-Hsd7 Inhibitor; Pre-Clinical Pharmaco-Kinetics; Reductive 17beta-Hudroxysteroid Dehydrogenases; Serum Sex-Hormone Balancing; Synergy Of Breast Cancer Drugs; Xenograft Tumor Shrinkage

$100,000

COVID-19 Variant Supplement - Innovative therapeutic approaches for the 2019-novel coronavirus

Principal investigatorCIHR2021Operating Grant: SARS-CoV-2 variants supplement stream 1

Principal investigators: Boivin, Guy; Baz Etchebarne, Mariana; Lin, Sheng-Xiang

Keywords: Antivirals; Combination; Coronavirus; Ferret; Hamster; Modeling; Polymerase; Repurposing; Synergy; Transcriptomic

$50,000

COVID-19 Variant Network - Innovative therapeutic approaches for the 2019-novel coronavirus

Principal investigatorCIHR2021Operating Grant: SARS-CoV-2 variants supplement stream 2

Principal investigators: Boivin, Guy; Finzi, Andrés; Liang, Chen; Lin, Sheng-Xiang

Keywords: Antivirals; Combination; Coronavirus; Ferret; Hamster; Modeling; Polymerase; Repurposing; Synergy; Transcriptomic

$100,000

Innovative therapeutic approaches for the 2019-novel coronavirus

Principal investigatorCIHR2020Operating Grant: COVID-19 - Therapeutics

Principal investigators: Boivin, Guy; Lin, Sheng-Xiang

Keywords: Antivirals; Combination; Coronavirus; Ferret; Hamster; Modeling; Polymerase; Repurposing; Synergy; Transcriptomic

$894,910

Sex as a Biological Variable Supplement - Innovative therapeutic approaches for the 2019-novel coronavirus

Principal investigatorCIHR2020Op Grant: Sex as a Biological Variable Supplement: COVID-19 Rapid Research FO

Principal investigators: Boivin, Guy; Lin, Sheng-Xiang

Keywords: Antivirals; Combination; Coronavirus; Ferret; Hamster; Modeling; Polymerase; Repurposing; Synergy; Transcriptomic

$49,780

3alpha-hydroxysteroid dehydrogenase type 3 as a modulator of human adipose tissue function and distribution

Co-investigatorCIHR2019Project Grant

Principal investigators: Tchernof, André

Keywords: Adipocyte; Androgen; Body Fat Distribution; Cortisol; Cortisone; Hydroxysteroid Dehydrogenase; Men; Obesity; Women

$401,625

New antiviral agents against herpes simplex viruses

Co-investigatorCIHR2009Proof of Principle Program - Phase I

Principal investigators: Boivin, Guy

Keywords: Animal; Antiviral; Dna Polymerase; Herpes Simplex Virus; Modeling; Resistance

$150,000

Sulfatase and aromatase pathways for estradiol synthesis in human breast cancer cells, tissues and animal models: identifying a combinatory therapy

Nominated PICIHR2009Operating Grant

Principal investigators: Lin, Sheng-Xiang

Keywords: A Combinatory Therapy For Breast Cancer; Animal Xenograft Models; Combined Use Of Enzyme Inhibitors; Enzyme Kinetics In Breast Cancer Cells; Enzymes Activating Estrogens; Sulfatase And Aromatase Pathways

$773,023

Superoxide dismutase-1 abnormalities associated with sporadic ALS

Co-investigatorCIHR2008Operating Grant

Principal investigators: Julien, Jean-Pierre

Keywords: Amyotrophic Lateral Sclerosis; Protein Aggregation; Protein Misfolding; Superoxide Dismutase

$397,008

Consortium for operation of a protein crystallographic synchrotron beamline

Co-investigatorNSERC2006Major Facilities Access Grants

Principal investigators: Sygusch, Jurgen

$348,750

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Something wrong or missing on this profile? Suggest a correction

Sheng-Xiang Lin

Research

Latest papers

Latest funding

Developing Potential Endocrine Therapy Controlling Estradiol and DHT by Targeting 17β-HSD7 Against ER+ Breast Cancer.

Search and prove of efficient inhibitors against papain-like protease from SARS-CoV-2.

A review on hemostatic materials: Past, present and future developments.

Synthesis and characterization of targeted 17β-hydroxysteroid dehydrogenase type 7 inhibitors.

New insights into the substrate inhibition of human 17β-hydroxysteroid dehydrogenase type 1.

Deep Drug Discovery of Mac Domain of SARS-CoV-2 (WT) Spike Inhibitors: Using Experimental ACE2 Inhibition TR-FRET Assay, Screening, Molecular Dynamic Simulations and Free Energy Calculations.

Search of Novel Small Molecule Inhibitors for the Main Protease of SARS-CoV-2.

CRIF1-CDK2 Interface Inhibitors Enhance Taxol Inhibition of the Lethal Triple-Negative Breast Cancer.

An unprecedented endocrine target for ovarian cancer: inhibiting 17β-HSD7 supresses cancer cell proliferation and arrests G2/M cycle.

The multi-specific human 17 beta-hydroxysteroid dehydrogenase type 7: Non-competitive inhibitors can target different catalyses to facilitate breast cancer treatment.

Pre-clinical pharmacokinetic and efficacy assays with an efficient 17beta-hydroxysteroid dehydrogenase type 7 inhibitor for breast cancer therapy

COVID-19 Variant Supplement - Innovative therapeutic approaches for the 2019-novel coronavirus

COVID-19 Variant Network - Innovative therapeutic approaches for the 2019-novel coronavirus

Innovative therapeutic approaches for the 2019-novel coronavirus

Sex as a Biological Variable Supplement - Innovative therapeutic approaches for the 2019-novel coronavirus

3alpha-hydroxysteroid dehydrogenase type 3 as a modulator of human adipose tissue function and distribution

New antiviral agents against herpes simplex viruses

Sulfatase and aromatase pathways for estradiol synthesis in human breast cancer cells, tissues and animal models: identifying a combinatory therapy

Superoxide dismutase-1 abnormalities associated with sporadic ALS

Consortium for operation of a protein crystallographic synchrotron beamline

Frequent collaborators

Donald Poirier

Guy Boivin

Boris Zhorov

Caroline Diorio

Sheng-Xiang Lin

Research

Latest papers

Latest funding

Developing Potential Endocrine Therapy Controlling Estradiol and DHT by Targeting 17&#x3b2;-HSD7 Against ER+ Breast Cancer.

Search and prove of efficient inhibitors against papain-like protease from SARS-CoV-2.

A review on hemostatic materials: Past, present and future developments.

Synthesis and characterization of targeted 17&#x3b2;-hydroxysteroid dehydrogenase type 7 inhibitors.

New insights into the substrate inhibition of human 17&#x3b2;-hydroxysteroid dehydrogenase type 1.

Deep Drug Discovery of Mac Domain of SARS-CoV-2 (WT) Spike Inhibitors: Using Experimental ACE2 Inhibition TR-FRET Assay, Screening, Molecular Dynamic Simulations and Free Energy Calculations.

Search of Novel Small Molecule Inhibitors for the Main Protease of SARS-CoV-2.

CRIF1-CDK2 Interface Inhibitors Enhance Taxol Inhibition of the Lethal Triple-Negative Breast Cancer.

An unprecedented endocrine target for ovarian cancer: inhibiting 17&#x3b2;-HSD7 supresses cancer cell proliferation and arrests G2/M cycle.

The multi-specific human 17 beta-hydroxysteroid dehydrogenase type 7: Non-competitive inhibitors can target different catalyses to facilitate breast cancer treatment.

Consortium for operation of a protein crystallographic synchrotron beamline

Frequent collaborators

Donald Poirier

Guy Boivin

Boris Zhorov

Caroline Diorio

Developing Potential Endocrine Therapy Controlling Estradiol and DHT by Targeting 17β-HSD7 Against ER+ Breast Cancer.

Synthesis and characterization of targeted 17β-hydroxysteroid dehydrogenase type 7 inhibitors.

New insights into the substrate inhibition of human 17β-hydroxysteroid dehydrogenase type 1.

An unprecedented endocrine target for ovarian cancer: inhibiting 17β-HSD7 supresses cancer cell proliferation and arrests G2/M cycle.